Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVernalis PLC Regulatory News (VER)

  • There is currently no data for VER

Block listing Interim Review

1 Oct 2018 14:57

RNS Number : 5737C
Vernalis PLC
01 October 2018
 

BLOCK LISTING SIX MONTHLY RETURN AND BLOCK LISTING APPLICATION

 

VERNALIS PLC (the "Company")

 

1 October 2018

 

Vernalis plc (LSE: VER) provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:

 

Name of applicant:

Vernalis plc

Name of scheme(s):

2007 Long Term Incentive Scheme ("LTIP"); 2012 Value Builder Plan ("VBP"); and

2016 Executive Incentive Plan ("EIP")

Period of return (from / to):

From: 29/Mar/2018

To: 01/Oct/2018

Balance of unallotted securities under scheme(s) from previous return:

Total of 2,149,159 Ordinary 1p Shares, split:

· Under LTIP = 360,485 Ordinary 1p Shares

· Under VBP = 1,788,674 Ordinary 1p Shares

· Under EIP = nil Ordinary 1p Shares

Plus: The amount by which the block scheme(s) has been increased or application has been made to increase since the date of the last return (if any increase has been applied for):

NIL

Less: Number of securities issued/allotted under scheme(s) during period:

Total of 166,376 Ordinary 1p Shares, split:

· Under LTIP = 39,405 Ordinary 1p Shares

· Under VBP = 126,971 Ordinary 1p Shares

Less: Number of securities forfeited under scheme(s) during period:

Total of 30,526 Ordinary 1p Shares:

· Under LTIP = 30,526 Ordinary 1p Shares

· Under VBP = nil Ordinary 1p Shares

· Under EIP = nil Ordinary 1p Shares

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

Total of 1,952,257 Ordinary 1p Shares, split:

· Under LTIP = 290,554 Ordinary 1p Shares

· Under VBP = 1,661,703 Ordinary 1p Shares

· Under EIP = nil Ordinary 1p Shares

Number and class of securities originally admitted and the date of admission (including any additions):

No. of Ordinary 1p Shares

Date on which Shares were Admitted to Trading

350,000

6 November 2013, plus

1,049,317

12 May 2014, plus

1,058,184

12 May 2015, plus

1,638,364

30 September 2015, plus

1,189,296

1 April 2016, plus

499,612

31 March 2017, plus

1,788,674

2 October 2017, plus

95,654

5 April 2018

 

-- ends --

 

Enquiries:

 

Vernalis plc:

+44 (0) 118 938 0015

Ian Garland, Chief Executive Officer

David Mackney, Chief Financial Officer

 

Canaccord plc (Nominated Adviser and Broker):

+44 (0) 20 7523 8000

Henry Fitzgerald-O'Connor

Emma Gabriel

 

Evercore (Financial Adviser):

+44 (0) 20 7653 6000

Julian Oakley

Alan Beirne

 

 

Notes to Editors

 

About Vernalis

Vernalis is a revenue generating, pharmaceutical company with significant expertise in drug development. The Group has two approved products: Moxatag®, a once-daily formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. Vernalis has also nine programmes in its NCE development pipeline in addition to significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Daiichi Sankyo, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis and Servier.

 

For further information about Vernalis, please visit www.vernalis.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRMBBJTMBAMBJP
Date   Source Headline
3rd May 20184:35 pmRNSPrice Monitoring Extension
27th Apr 20181:31 pmRNSForm 8.5 (EPT/RI)
20th Apr 20185:53 pmRNSHolding(s) in Company
20th Apr 20185:52 pmRNSHolding(s) in Company
20th Apr 20182:42 pmRNSForm 8.3 - Vernalis plc
20th Apr 201812:57 pmRNSHolding(s) in Company
20th Apr 201810:01 amRNSForm 8.3 - Vernalis Plc
20th Apr 201810:00 amRNSForm 8.3 - Vernalis PLC
18th Apr 20184:35 pmRNSPrice Monitoring Extension
17th Apr 20182:15 pmRNSForm 8.3 - Vernalis Plc
29th Mar 201810:08 amRNSPublic Opening Position Disclosure
29th Mar 20187:00 amRNSBlock Listing 6 Montly Return
28th Mar 20187:00 amRNSUnaudited Interim Results for 6 months to 31/12/17
22nd Mar 201810:47 amRNSForm 8.5 (EPT/RI)
21st Mar 20184:05 pmRNSRule 2.9 Announcement
21st Mar 20181:11 pmRNSForm 8.3 - Vernalis Plc
20th Mar 20183:10 pmRNSForm 8.3 - Vernalis Plc
20th Mar 20183:10 pmRNSForm 8.3 - Vernalis Plc
20th Mar 20183:08 pmRNSForm 8.3 - Vernalis Plc
20th Mar 20182:42 pmRNSForm 8.3 - Vernalis PLC
19th Mar 20181:41 pmRNSForm 8.3 - Vernalis Plc
16th Mar 20182:47 pmRNSForm 8.3 - Vernalis plc
16th Mar 20182:25 pmRNSForm 8.5 (EPT/RI)
16th Mar 20181:00 pmRNSForm 8.3 - Vernalis Plc
16th Mar 201810:08 amRNSForm 8.3 - Vernalis Plc
15th Mar 20183:14 pmRNSForm 8.3 - Vernalis Plc
15th Mar 20187:00 amRNSUpdate on Strategic Review and Formal Sale Process
2nd Mar 20184:40 pmRNSSecond Price Monitoring Extn
2nd Mar 20184:35 pmRNSPrice Monitoring Extension
1st Mar 20184:52 pmRNSHolding(s) in Company
28th Feb 20187:00 amRNSVernalis plc Trading and Corporate Update
8th Feb 20184:35 pmRNSPrice Monitoring Extension
29th Dec 20177:00 amRNSTotal Voting Rights
27th Dec 20174:40 pmRNSSecond Price Monitoring Extn
27th Dec 20174:35 pmRNSPrice Monitoring Extension
14th Dec 20171:15 pmRNSVernalis Results of Annual General Meeting
14th Dec 20177:00 amRNSAGM Statement
13th Dec 20177:00 amRNSVernalis + Daiichi Sankyo Enter Collaboration
6th Dec 20177:00 amRNSVernalis and Servier Achieve Research Milestone
5th Dec 20174:40 pmRNSSecond Price Monitoring Extn
5th Dec 20174:35 pmRNSPrice Monitoring Extension
30th Nov 201712:34 pmRNSTotal Voting Rights
2nd Nov 20177:00 amRNSNotice of Annual Report and AGM
31st Oct 20177:00 amRNSTotal Voting Rights
29th Sep 20177:00 amRNSBlock listing Interim Review
12th Sep 20177:00 amRNSResults Announcement for the Year Ended 30/06/2017
7th Aug 20177:00 amRNSFDA Issues Complete Response Letter on CCP-08 NDA
18th Jul 20177:00 amRNSYear-End Trading Update and Notice of Results
30th Jun 20177:00 amRNSTotal Voting Rights
31st May 20177:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.